The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Open accessAbstract
BACKGROUND: The standard treatment for hepatitis C virus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome side effects. We evaluated sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and interferon-free regimens for the treatment of HCV infection. METHODS: We provided open-label treatment to eight groups of patients. A total of 40 previously untreated patients with HCV genotype 2 or 3 infection were randomly assigned to four groups; all four groups received sofosbuvir (at a dose of 400 mg once daily) plus ribavirin for 12 weeks. Three of these groups also received peginterferon alfa-2a for 4, 8, or 12 weeks. Two additional groups of previously untreated patients with HCV genotype 2 or 3 infection received sofosbuvir monotherapy for 12 weeks or sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks. Two groups of patients with HCV genotype 1 infection received sofosbuvir and ribavirin for 12 weeks: 10 patients with no response to prior treatment and 25 with no previous treatment. We report the rate of sustained virologic response 24 weeks after therapy. RESULTS: Of the 40 patients who underwent randomization, all 10 (100%) who received sofosbuvir plus ribavirin without interferon and all 30 (100%) who received sofosbuvir plus ribavirin for 12 weeks and interferon for 4, 8, or 12 weeks had a sustained virologic response at 24 weeks. For the other patients with HCV genotype 2 or 3 infection, all 10 (100%) who received sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks had a sustained virologic response at 24 weeks, as did 6 of 10 (60%) who received sofosbuvir monotherapy. Among patients with HCV genotype 1 infection, 21 of 25 previously untreated patients (84%) and 1 of 10 with no response to previous therapy (10%) had a sustained virologic response at 24 weeks. The most common adverse events were headache, fatigue, insomnia, nausea, rash, and anemia. CONCLUSIONS: Sofosbuvir plus ribavirin for 12 weeks may be effective in previously untreated patients with HCV genotype 1, 2, or 3 infection. (Funded by Pharmasset and Gilead Sciences; ClinicalTrials.gov number, NCT01260350.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,514
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Kuntzen, T., Timm, J., Berical, A., Lennon, N., Berlin, A. M., Young, S. K., Lee, B., Heckerman, D., Carlson, J., Reyor, L. L., et al. (2008) · Hepatology · doi:10.1002/hep.22549 · Cited by 349
Gane, E. J., Roberts, S. K., Stedman, C. A., Angus, P. W., Ritchie, B., Elston, R., Ipe, D., Morcos, P. N., Baher, L., Najera, I., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61384-0 · Cited by 335
Self-citationSurprisingly Small Effect of Antiviral Treatment in Patients with Hepatitis C
Falck-Ytter, Y., Kale, H., Mullen, K. D., Sarbah, S. A., Sorescu, L., & McCullough, A. J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-4-200202190-00008 · Cited by 301
Qu, A., Taylor, M., Xue, X., Matsubara, T., Metzger, D., Chambon, P., Gonzalez, F. J., & Shah, Y. M. (2011) · Hepatology · doi:10.1002/hep.24400 · Cited by 181
The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C
Thomas, E., Ghany, M. G., & Liang, T. J. (2012) · Antiviral chemistry & chemotherapy · doi:10.3851/imp2125 · Cited by 178
McCown, M. F., Rajyaguru, S., Le Pogam, S., Ali, S., Jiang, W.-R., Kang, H., Symons, J., Cammack, N., & Najera, I. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01317-07 · Cited by 164
Viral Determinants of Resistance to Treatment in Patients with Hepatitis C
Wohnsland, A., Hofmann, W. P., & Sarrazin, C. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-06 · Cited by 158
Paeshuyse, J., Dallmeier, K., & Neyts, J. H. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.10.030 · Cited by 116
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
(2013) · Chinese Science Bulletin · doi:10.1007/11434.1861-9541 · Cited by 1,955
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Self-citationStructure of the RNA-dependent RNA polymerase from COVID-19 virus
Gao, Y., Yan, L., Huang, Y., Liu, F., Zhao, Y., Cao, L., Wang, T., Sun, Q., Ming, Z., Zhang, L., et al. (2020) · Science · doi:10.1126/science.abb7498 · Cited by 1,609
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
Jordheim, L. P., Durantel, D., Zoulim, F., & Dumontet, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4010 · Cited by 1,211
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A. S., Hinestrosa, F., Thuluvath, P. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306218 · Cited by 1,190
Self-citationSofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090
Self-citationLawitz, E., Sulkowski, M. S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z. M., Corregidor, A., DeJesus, E., Pearlman, B., Rabinovitz, M., Gitlin, N., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61036-9 · Cited by 818
Self-citationAnti-HCV, nucleotide inhibitors, repurposing against COVID-19
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117477 · Cited by 715
ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Ferenci, P., Bernstein, D., Lalezari, J., Cohen, D., Luo, Y., Cooper, C., Tam, E., Marinho, R. T., Tsai, N., Nyberg, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402338 · Cited by 693
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
Scheel, T. K. H., & Rice, C. M. (2013) · Nature Medicine · doi:10.1038/nm.3248 · Cited by 554
Lawitz, E., Poordad, F. F., Pang, P. S., Hyland, R. H., Ding, X., Mo, H., Symonds, W. T., McHutchison, J. G., & Membreno, F. E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62121-2 · Cited by 547
Self-citationNew Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Pawlotsky, J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.003 · Cited by 518
Current and Future Therapies for Hepatitis C Virus Infection
Liang, T. J., & Ghany, M. G. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1213651 · Cited by 490
Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., Foster, G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J., et al. (2013) · Hepatology · doi:10.1002/hep.26431 · Cited by 488
Treatment of Hepatitis C: A Systematic Review
Kohli, A., Shaffer, A., Sherman, A., & Kottilil, S. (2014) · JAMA · doi:10.1001/jama.2014.7085 · Cited by 426
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Sarrazin, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.09.011 · Cited by 423
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
Bartenschlager, R., Lohmann, V., & Penin, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3046 · Cited by 402
Structural basis for RNA replication by the hepatitis C virus polymerase
Appleby, T. C., Perry, J. K., Murakami, E., Barauskas, O., Feng, J., Cho, A., Fox, D., Wetmore, D. R., McGrath, M. E., Ray, A. S., et al. (2015) · Science · doi:10.1126/science.1259210 · Cited by 339
Curry, M. P., Forns, X., Chung, R. T., Terrault, N. A., Brown, R., Fenkel, J. M., Gordon, F., O’Leary, J., Kuo, A., Schiano, T., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.023 · Cited by 334
Self-citationKoh, C., Li, Q., & Liang, J. (2016) · Clinical Virology · doi:10.1128/9781555819439.ch54 · Cited by 321
Durand, F., Levitsky, J., Cauchy, F., Gilgenkrantz, H., Soubrane, O., & Francoz, C. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.009 · Cited by 320
Martin, N. K., Hickman, M., Hutchinson, S. J., Goldberg, D. J., & Vickerman, P. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit296 · Cited by 314
Structural biology of SARS-CoV-2: open the door for novel therapies
Yan, W., Zheng, Y., Zeng, X., He, B., & Cheng, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00884-5 · Cited by 291
Osinusi, A., Meissner, E. G., Lee, Y.-J., Bon, D., Heytens, L., Nelson, A., Sneller, M., Kohli, A., Barrett, L., Proschan, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.109309 · Cited by 291
Self-citationGlobal control of hepatitis C: where challenge meets opportunity
Thomas, D. L. (2013) · Nature Medicine · doi:10.1038/nm.3184 · Cited by 280
Hepatitis C virus drug resistance–associated substitutions: State of the art summary
Lontok, E., Harrington, P., Howe, A., Kieffer, T., Lennerstrand, J., Lenz, O., McPhee, F., Mo, H., Parkin, N., Pilot‐Matias, T., et al. (2015) · Hepatology · doi:10.1002/hep.27934 · Cited by 275
Yates, M. K., & Seley-Radtke, K. L. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2018.11.016 · Cited by 275
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
Kowdley, K. V., Lawitz, E., Poordad, F., Cohen, D. E., Nelson, D. R., Zeuzem, S., Everson, G. T., Kwo, P., Foster, G. R., Sulkowski, M. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306227 · Cited by 255
Advances in hepatitis C therapy: what is the current state - what come's next?
Zopf, S. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i3.139 · Cited by 91
Tissue Determinants of Antiviral Immunity in the Liver
Wohlleber, D., & Knolle, P. A. (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2365-3900 · Cited by 3
“…C, a curative directly acting antiviral therapy exists, chronic hepatitis B can currently only be treated with nucleo(s)tide analogues, suppressing viral replication but not leading to a final cure from infection because of HBV establishes an extrachromosomal persistence form, the cccDNA [7].”
Metadata
- Authors
- Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Symonds, W. T., Hindes, R. G., & Berrey, M. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-01-03
- Volume
- 368
- Issue
- 1
- Pages
- 34-44
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2222306685
- Cited by
- 764
- References
- 12
- FWCI
- 92.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.